

STATE OF HAWAII NARCOTICS ENFORCEMENT DIVISION

Department of Public Safety 3375 Koapaka Street, Suite D-100 Honolulu, Hawaii 96819

September 8, 2014

TED SAKAI DIRECTOR

Martha Torney
Deputy Director
Administration

Max Otani
Deputy Director
Corrections

Shawn Tsuha Deputy Director Law Enforcement

No. <u>Posted at LT Gov office</u> 9-8-14

NOTICE OF FEDERAL SCHEDULING ACTIONS

Section 329-11(d) states that if a substance is added, deleted or rescheduled under federal law and notice of the designation is given to the department then the department shall recommend to the legislature that a corresponding change in Hawaii law be made. The Department was given notice that the following depressant drug was placed into Schedule IV by the Federal Government:

[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (suvorexant), including its salts, isomers, and salts of isomers.

On August 28, 2014, the Department was given notice that [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (suvorexant), including its salts, isomers, and salts of isomers, into schedule IV of the Controlled Substances Act (CSA). This scheduling action is pursuant to the CSA which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule IV controlled substances on persons who handle (manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities with, or possess) or propose to handle suvorexant. The DEA placed an effective date of September 29, 2014 on this scheduling action.

Section 329-20, Hawaii Revised Statutes, is amended by amending subsection (g) to read as follows:

§329-20 Schedule IV. (a) The controlled substances listed in this section are included in schedule IV.

- (b) Depressants. Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, esters, ethers, and salts of isomers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation, that has a degree of danger or probable danger associated with a depressant effect on the central nervous system:
 - (1) Alprazolam;
 - (2) Barbital;
 - (3) Bromazepam;
 - (4) Butorphanol;
 - (5) Camazepam;
 - (6) Carisoprodol;
 - (7) Chloral betaine;
 - (8) Chloral hydrate;

(9) Chlordiazepoxide; (10) Clobazam; (11) Clonazepam; (12) Clorazepate; (13) Clotiazepam; (14) Cloxazolam; (15) Delorazepam; (16) Dichloralphenazone (Midrin); (17) Diazepam; (18) Estazolam; (19) Ethchlorvynol; (20) Ethinamate; (21) Ethyl loflazepate; (22) Fludiazepam; (23) Flunitrazepam; (24) Flurazepam; (25) Fospropofol (Lusedra); (26) Halazepam; (27) Haloxazolam; (28) Ketazolam; (29) Loprazolam; (30) Lorazepam; (31) Lormetazepam; (32) Mebutamate; (33) Medazepam; (34) Meprobamate; (35) Methohexital; (36) Methylphenobarbital (mephorbarbital); (37) Midazolam; (38) Nimetazepam; (39) Nitrazepam; (40) Nordiazepam; (41) Oxazepam; (42) Oxazolam; (43) Paraldehyde; (44) Petrichloral; (45) Phenobarbital; (46) Pinazepam; (47) Prazepam; (48) Quazepam; (49) Suvorexant; [(49)](50) Temazepam; [(50)](51) Tetrazepam; [(51)](52) Triazolam; [(52)](53) Zaleplon; [(53)](54) Zolpidem; and [(54)](55) Zopiclone (Lunesta).

This Federal scheduling changes shall take effect on September 29, 2014 as required under Section 329-11(d) HRS.